生产制造如何赢得或输掉新冠疫苗竞赛
其共同特点是能快速开发并扩大产能以满足全球大规模接种需求。
要点
- 32种疫苗获紧急使用授权,仅5种对全球疫情进程产生显著影响。
- 成功因素包括商业化经验、质量体系、工艺开发、灵活设施与熟练劳动力、合作、物料获取及公平分销网络。
研究设计与样本
- 基于公开信息,对每种有可用信息的疫苗和技术,审查其开发、放大、检测、技术转移、全面生产及化学、制造和控制(CMC)监管互动。
主要发现
- 截至2021年底,32种疫苗获国家监管机构或世界卫生组织紧急使用授权,其中27种对全球疫情进程影响甚微。
- 5种疫苗生产商的共同特点是能快速开发并扩大疫苗生产,提供大规模免疫所需的大量产能。
临床怎么用
- 作者建议采取 proactive actions 以更好地准备未来大流行应对,关键成功因素包括:以往商业化和审批经验、稳健的质量体系、严格的工艺开发策略、配备熟练劳动力的灵活生产设施、合作、获取耗材、试剂和佐剂(如相关)以及全球疫苗生产网络的公平分销。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The development of vaccines for COVID-19 occurred at an unprecedented pace, and 32 vaccines using a broad range of technologies had received authorization for use on an emergency basis by the end of 2021, from either a national regulatory authority or the World Health Organization. However, 27 of those 32 vaccines had little impact on the global course of the pandemic. Only five vaccines, from AstraZeneca, Pfizer/BioNTech, Sinovac, Moderna, and Sinopharm, were manufactured, authorized, and distributed in time to significantly impact the number of deaths worldwide. Together, these five vaccines averted an estimated 17 million deaths in the first year of the vaccination campaign. The shared characteristic of these five manufacturers was their ability to rapidly develop and scale up vaccine production to deliver the large manufacturing volumes required to immunize large segments of the global population. Because the development and manufacturing of these vaccines was generally on the critical path to authorization and supply, the technical activities involved with development, scale-up, testing, technology transfer, and full-scale manufacturing, as well as aspects of the Chemistry, Manufacturing, and Controls (CMC) regulatory interactions, are examined for each vaccine and technology for which information is available in the public domain to provide lessons learned and recommendations on proactive actions to better prepare us for a future pandemic response. The critical success factors include prior experience with commercialization and approval, robust quality systems, rigorous process development strategies, flexible manufacturing facilities with a skilled workforce, collaboration, access to consumables, reagents, and adjuvants (if relevant), and an equitable distribution of the global vaccine manufacturing network.
引用
- King ML. How manufacturing won or lost the COVID-19 vaccine race. Vaccine. 2024. PMID: 38228438. doi:10.1016/j.vaccine.2023.12.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。